New Analysis Links Shingles Vaccine to Slower Dementia, Fewer Deaths as US Cases Top 1 Million by 2060
Updated
Updated · Vox.com · Jun 15
New Analysis Links Shingles Vaccine to Slower Dementia, Fewer Deaths as US Cases Top 1 Million by 2060
3 articles · Updated · Vox.com · Jun 15
Summary
A late-2025 reanalysis of Welsh data found shingles vaccination was associated not just with lower dementia risk, but with slower progression after diagnosis and fewer dementia-related deaths.
That adds to earlier signals: a Wales study found vaccinated older adults were 20% less likely to develop dementia over seven years, and a Canadian study in people over 70 reported a similar pattern.
Researchers still say the evidence is not conclusive, and US guidance recommends shingles shots starting at age 50 unless adults are immunocompromised.
The broader backdrop is mixed: new US dementia cases are projected to rise from 514,000 in 2020 to more than 1 million a year by 2060, even as age-specific dementia rates in wealthy countries have fallen about 13% per decade since the late 1980s.
Much of that decline is tied to modifiable midlife risks—blood pressure, LDL cholesterol, smoking, hearing and vision loss, exercise and education—with a 2024 Lancet commission estimating up to 45% of cases could be prevented or delayed.
Are routine vaccinations now our most accessible tool for delaying the onset of dementia?
Why do vaccines appear to offer stronger protection against dementia in women than in men?
Is a key ingredient in shingles and RSV vaccines the secret weapon for preventing Alzheimer's disease?
Shingles Vaccine Shows Promise in Reducing Dementia Risk: Key Findings and Future Directions
Overview
Recent research highlights a promising link between receiving the shingles vaccine and a reduced risk of developing dementia. Studies suggest that the vaccine’s benefits may go beyond just preventing shingles, potentially influencing neurological health. Notably, a major follow-up study found that the shingles vaccine could help prevent the onset of dementia and even slow its progression in those already affected. This effect was observed in reduced risk of dying from dementia among vaccinated individuals. These findings, supported by Dr. Pascal Geldsetzer’s team, point to the vaccine’s potential therapeutic properties for dementia, making it a significant development in public health.